HPLC has long been regarded as the standard for antibody quantitation. It is extensively used in drug development processes to quantitate antibodies in cell culture supernatants, fed-batch flasks, and bioreactors. However, HPLC quantitation cannot be performed in crude matrices, is unable to detect low titers, suffers from low throughput, and requires extensive cleaning and maintenance. In contrast, the Octet platform offers a microfluidics-free, higher throughput solution to meet quantitation needs with accuracy, precision, specificity in crude matrices, and a wider dynamic range for detection of low to high titers.
ForteBio’s Octet platform (Figure 1) provides comprehensive characterization across a range of applications in various stages of drug development, including antibody and protein quantitation, kinetic characterization of proteins and small molecules, and validation of reagents. The Octet platform circumvents the limitations of ELISA and HPLC analysis, enabling informed decisions to be made earlier in bioprocess development.
Octet systems perform sample analysis in 96- and 384-well microplate formats, processing up to 16 samples in parallel. The simple Dip and Read™ approach enables streamlined workflows and rapid quantitation of 96 samples in as little as 20 minutes, or 384 samples in 70 minutes.
Octet systems measure binding signal using a proprietary optical technology called Bio-layer interferometry (BLI). Biosensors coated with capture molecules dip in to samples and the concentration of the target antibody in the sample is measured via a direct binding assay. In a typical quantitation assay, a standard curve is generated using known amounts of the antibody, and unknown sample concentrations are extrapolated from the standard curve.